Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...

Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced ...

Guggenheim has initiated coverage of Metsera (MTSR) with a buy rating, citing the company's obesity drug candidates. Read ...

We recently published a list of 10 Stocks Insiders Spent The Most Money On Recently. In this article, we are going to take a ...

Evercore ISI analyst Umer Raffat initiated coverage of Metsera (MTSR) with an Outperform rating. Metsera has a full portfolio of GLP-1 ...

Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...

BofA initiated coverage of Metsera (MTSR) with a Buy rating and $38 price target implying over 20% share upside. Metsera is a clinical-stage ...

In this article, we are going to take a look at where Metsera (NASDAQ:MTSR) stands against other stocks insiders spent the most money on recently. As the broader market continues to rise this year ...

Metsera’s GLP-1 peptide has a long half-life, meaning it could be administered once a month. The company is ready to scale up ...

Assess the latest information about the Metsera stock. Our team of expert financial journalists are ready to bring you today's top MTSR shares news to keep you ahead of the curve. Metsera Announces ...

NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) ("Metsera"), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated ...